PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26991852-7	2016	The results showed that coumestrol-induced phosphorylation of ERK1/2 MAPK and P90RSK was blocked by U0126.	U 0126	100-105	mitogen-activated protein kinase 3	Sus scrofa	62-68	
30248419-6	2018	Hoechst 33258 staining and Annexin V/PI analysis exhibited that U0126, the ERK1/2 inhibitor, aggravated OTA-induced apoptosis.	U 0126	64-69	mitogen-activated protein kinase 3	Sus scrofa	75-81	
27775163-8	2017	Moreover, phosphorylation of AKT, ERK1/2, P38, and JNK proteins were suppressed by their inhibitors wortmannin, U0126, SB203580, and SP600125, respectively.	U 0126	112-117	mitogen-activated protein kinase 3	Sus scrofa	34-40	
27605672-8	2016	Furthermore, the replication of CSFV was markedly inhibited in PK-15 cells treated with U0126, a specific inhibitor for MEK1/2/ERK1/2, whereas MEK2 did not affect CSFV replication after blocking the interferon-induced Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway by ruxolitinib, a JAK-STAT-specific inhibitor.	U 0126	88-93	mitogen-activated protein kinase 3	Sus scrofa	127-133	
25542137-10	2015	Knockdown of p38 and ERK1/2 by their respective specific siRNAs or inhibition of p38 and ERK1/2 phosphorylation by their respective inhibitors (SB203580 and U0126) eliminated the increase in PCV2 replication induced by OTA.	U 0126	157-162	mitogen-activated protein kinase 3	Sus scrofa	89-95	
26520031-6	2016	Ten ng/ml IL-1beta increased levels of phosphorylated (p)-ERK1/2 proteins in pLE cells within 15 min post-treatment, and this IL-1beta-induced phosphorylated status was inhibited by increasing doses of U0126 (ERK1/2 inhibitor).	U 0126	202-207	mitogen-activated protein kinase 3	Sus scrofa	58-64	
24508636-9	2014	In the presence of the ERK1/2 MAPK inhibitor (U0126), IGF-I-induced AKT1 phosphorylation was not affected, whereas the PI3K inhibitor (LY294002) decreased IGF-I-induced phosphorylation of ERK1/2 and AKT1 proteins, and both the PI3K-AKT1 and ERK1/2 MAPK pathways were blocked by LY294002.	U 0126	46-51	mitogen-activated protein kinase 3	Sus scrofa	23-29	
24508636-9	2014	In the presence of the ERK1/2 MAPK inhibitor (U0126), IGF-I-induced AKT1 phosphorylation was not affected, whereas the PI3K inhibitor (LY294002) decreased IGF-I-induced phosphorylation of ERK1/2 and AKT1 proteins, and both the PI3K-AKT1 and ERK1/2 MAPK pathways were blocked by LY294002.	U 0126	46-51	mitogen-activated protein kinase 3	Sus scrofa	188-194	
24508636-9	2014	In the presence of the ERK1/2 MAPK inhibitor (U0126), IGF-I-induced AKT1 phosphorylation was not affected, whereas the PI3K inhibitor (LY294002) decreased IGF-I-induced phosphorylation of ERK1/2 and AKT1 proteins, and both the PI3K-AKT1 and ERK1/2 MAPK pathways were blocked by LY294002.	U 0126	46-51	mitogen-activated protein kinase 3	Sus scrofa	188-194	
14656772-6	2004	Inhibition of either ERK1/2, PKC, or the inhibitory G protein (Gi) with U-0126, bisindolylmaleimide HCl, and pertussis toxin, respectively, blocked (P < 0.05) the increase in IL-6 expression caused by LPS.	U 0126	72-78	mitogen-activated protein kinase 3	Sus scrofa	21-27	
22040433-10	2011	Furthermore, 30-minute pretreatment with 10 micromol/L U0126, specific antagonist for ERK kinase (MEK) prevented the increase in phosphorylation of ERK1/ERK2 and abolished cell cycle progression and the proliferation of PASMCs induced by sildenafil.	U 0126	55-60	mitogen-activated protein kinase 3	Sus scrofa	148-152	
19032432-8	2010	Pre-treatment of sperm with U0126, a MEK inhibitor, significantly suppressed both the AR and phosphorylation of MEK/ERK1 in a dose-dependent manner.	U 0126	28-33	mitogen-activated protein kinase 3	Sus scrofa	116-120	
16310170-6	2006	Furthermore, inhibition of ERK1/2 signaling pathway by U-0126 enhances caspase-3 activity and sets up programmed cell death.	U 0126	55-61	mitogen-activated protein kinase 3	Sus scrofa	27-33	
16310170-7	2006	Both IL-1beta and exogenous C(2)-ceramide effects are reproduced by U-0126 so illustrating the implication of ERK1/2 down-regulation in both caspase-3 activation and apoptosis induction.	U 0126	68-74	mitogen-activated protein kinase 3	Sus scrofa	110-116